Evidence map›Paper›PMID 29321155›Full record

Trial reportBlood2018

Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency.

Amy D Shapiro, Charles Nakar, Joseph M Parker, Gary R Albert, John E Moran, Karen Thibaudeau, Neelam Thukral, Brandon M Hardesty, Pierre Laurin, Per Morten Sandset

3 registry-linked trialsAbstract readClinical Trial, Phase IIClinical Trial, Phase IIIMulticenter Study
In one paragraph

Trial report in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
1.2field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02690714 phase2 / phase3completednot on this map

A Phase 2/3, Open-Label, Repeat-Dose Study of the Pharmacokinetics, Efficacy, and Safety of Prometic Plasminogen Intravenous Infusion in Subjects With Hypoplasminogenemia

TypeinterventionalSponsorPrometic Biotherapeutics, Inc.Ran2016 to 2018Enrolled15ConditionsHypoplasminogenemia, Congenital Plasminogen DeficiencyArmsPlasminogen (Human) intravenous
NCT03797495 recruitingnot on this map

Hypoplasminogenemia: An International RetroSpecTive and PrOspective CohoRt StudY (HISTORY)

TypeobservationalSponsorIndiana Hemophilia &Thrombosis Center, Inc.Ran2018 to 2029Enrolled100ConditionsPlasminogen Deficiency
NCT04275232 phase3enrolling by invitationnot on this mapstarted 2025, after this paper: background citation

The Use of Allogenic Plasma Aliquots as a Source of Plasminogen in the Treatment of Ligneous Conjunctivitis, Clinical Trial of One Case

TypeinterventionalSponsorDorothy Bautista, MDRan2025 to 2025Enrolled1ConditionsLigneous Conjunctivitis, Left EyeArmsAllogenic plasma aliquots, a source of plasminogen
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 46 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. The Pharmaceutical Year that was, 2021.Pharmaceutical medicine · 2021
    Article
  16. Plasminogen Receptors and Fibrinolysis.International journal of molecular sciences · 2021
    Review
  17. Lysis of cold-storage-induced microvascular obstructions for ex vivo revitalization of marginal human kidneys.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021
    Article
  18. The plasminogen receptor, Plg-RCell death & disease · 2020
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Amy D ShapiroIndiana Hemophilia and Thrombosis Center, Indianapolis, IN.
Charles NakarIndiana Hemophilia and Thrombosis Center, Indianapolis, IN.
Joseph M ParkerPrometic Biotherapeutics Inc., Rockville, MD.
Gary R AlbertPrometic Biotherapeutics Inc., Rockville, MD.
John E MoranPrometic Life Sciences, Laval, QC, Canada; and.
Karen ThibaudeauPrometic Life Sciences, Laval, QC, Canada; and.
Neelam ThukralIndiana Hemophilia and Thrombosis Center, Indianapolis, IN.
Brandon M HardestyIndiana Hemophilia and Thrombosis Center, Indianapolis, IN.
Pierre LaurinPrometic Life Sciences, Laval, QC, Canada; and.
Per Morten SandsetDepartment of Hematology, Oslo University Hospital and University of Oslo, Oslo, Norway.
Indiana Hemophilia and Thrombosis Center · USIntegrated BioTherapeutics (United States) · USOslo University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Congenital plasminogen deficiency is caused by mutations in

Indexed as

Blood Coagulation Disorders, InheritedPlasminogenAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleHumansMaleMiddle AgedPlasminogen

Identifiers

PMID29321155
PMCPMC5865234
OpenAlexW2784049527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.